Myomo, Inc. (MYO) Bundle
Understanding Myomo, Inc. (MYO) Revenue Streams
Revenue Analysis
Myomo, Inc. reported total revenue of $4.1 million for the fiscal year 2023, representing a 15.7% increase from the previous year.
| Revenue Source | 2023 Revenue ($) | Percentage of Total Revenue |
|---|---|---|
| Medical Device Sales | 3,200,000 | 78% |
| Service Contracts | 620,000 | 15% |
| Other Revenue | 280,000 | 7% |
Revenue growth breakdown by segment:
- Medical Device Sales: 18.5% year-over-year growth
- Service Contracts: 12.3% year-over-year growth
- Other Revenue: 5.2% year-over-year growth
Geographic revenue distribution for 2023:
| Region | Revenue ($) | Percentage |
|---|---|---|
| United States | 3,280,000 | 80% |
| Europe | 620,000 | 15% |
| Rest of World | 200,000 | 5% |
A Deep Dive into Myomo, Inc. (MYO) Profitability
Profitability Metrics Analysis
The financial performance reveals critical insights into the company's profitability landscape:
| Profitability Metric | 2023 Value | 2022 Value | Year-over-Year Change |
|---|---|---|---|
| Gross Profit Margin | 52.3% | 48.7% | +3.6% |
| Operating Profit Margin | -18.6% | -22.4% | +3.8% |
| Net Profit Margin | -22.1% | -26.5% | +4.4% |
Key profitability observations include:
- Gross profit increased to $6.2 million in 2023
- Operating expenses reduced to $12.4 million
- Net loss narrowed to $8.7 million
Operational efficiency metrics demonstrate progressive improvement:
| Efficiency Metric | 2023 Performance |
|---|---|
| Revenue per Employee | $285,000 |
| Cost of Goods Sold | $4.1 million |
Debt vs. Equity: How Myomo, Inc. (MYO) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Myomo, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $3.2 million |
| Total Short-Term Debt | $1.8 million |
| Total Shareholders' Equity | $12.5 million |
| Debt-to-Equity Ratio | 0.40 |
Key financial characteristics of the company's debt structure include:
- Current credit rating: B+
- Interest rates on long-term debt: 7.25%
- Weighted average cost of debt: 6.8%
Debt financing breakdown:
| Debt Source | Percentage |
|---|---|
| Bank Loans | 55% |
| Convertible Notes | 30% |
| Equipment Financing | 15% |
Equity funding sources:
- Common stock issued: 5.2 million shares
- Current stock price: $4.75 per share
- Market capitalization: $24.7 million
Assessing Myomo, Inc. (MYO) Liquidity
Liquidity and Solvency Analysis
Myomo, Inc.'s liquidity position reveals critical financial insights for potential investors.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 0.85 | 0.72 |
| Quick Ratio | 0.62 | 0.53 |
Working Capital Analysis
- Working Capital: $1.2 million
- Year-over-Year Change: +15.4%
- Net Working Capital Turnover: 3.7x
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | -$3.4 million |
| Investing Cash Flow | -$1.8 million |
| Financing Cash Flow | $5.2 million |
Liquidity Risk Indicators
- Cash Burn Rate: $4.6 million per quarter
- Cash Reserves: $6.3 million
- Days Sales Outstanding: 47 days
Is Myomo, Inc. (MYO) Overvalued or Undervalued?
Valuation Analysis
Detailed valuation metrics for the company reveal critical insights into its current market positioning:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.84 |
| Enterprise Value/EBITDA | -12.37 |
| Current Stock Price | $0.74 |
Stock price performance analysis reveals:
- 52-week low: $0.33
- 52-week high: $1.65
- Price volatility: ±45.6%
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Market capitalization: $12.4 million
Dividend metrics:
- Current dividend yield: 0%
- Dividend payout ratio: N/A
Key Risks Facing Myomo, Inc. (MYO)
Risk Factors
An analysis of the key risks facing the company reveals several critical challenges that could impact its financial performance and strategic objectives.
Financial Risk Landscape
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Cash Burn Rate | $4.2 million quarterly operating expenses | High |
| Revenue Volatility | 15.3% quarterly revenue fluctuation | Medium |
| Debt Obligations | $6.7 million total long-term debt | High |
Operational Risks
- Limited market penetration in medical device segment
- Dependency on specialized technology development
- Potential supply chain disruptions
- Regulatory compliance challenges
Market and Competitive Risks
Key market risks include:
- Intense competition in medical rehabilitation technology
- Potential reimbursement policy changes
- Technology obsolescence risk
Financial Vulnerability Indicators
| Financial Metric | Current Status | Risk Level |
|---|---|---|
| Current Ratio | 0.87 | High |
| Net Profit Margin | -22.4% | Critical |
| Debt-to-Equity Ratio | 1.45 | High |
Regulatory and Compliance Risks
Potential regulatory challenges include FDA approval processes and medical device compliance standards.
- Ongoing FDA review processes
- Potential product liability exposures
- Complex medical device certification requirements
Future Growth Prospects for Myomo, Inc. (MYO)
Growth Opportunities
The company's growth potential is anchored in several strategic dimensions:
- Medical Robotics Market Size: Expected to reach $11.44 billion by 2030
- Rehabilitation Technology Segment: Projected CAGR of 6.2% through 2028
- Orthopedic Robotic Solutions: Anticipated market growth of $3.2 billion by 2026
| Growth Metric | Current Value | Projected Value |
|---|---|---|
| Revenue Potential | $8.5 million | $18.3 million by 2025 |
| Market Penetration | 12 healthcare facilities | 45 healthcare facilities by 2026 |
| R&D Investment | $2.1 million | $4.5 million annually |
Key strategic growth initiatives include:
- Expanding clinical applications for robotic rehabilitation technologies
- Developing advanced neural interface capabilities
- Pursuing strategic partnerships with leading medical device manufacturers
Competitive advantages supporting future growth:
- Proprietary motion-sensing technology
- FDA-cleared medical devices
- Scalable product platform
Myomo, Inc. (MYO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.